A three-amino-acid peptide targeting blood vessel health—with one in vitro study showing gene expression changes and no animal trials, no human trials, and no published pharmacological data beyond cell dishes.

Vesugen is a tripeptide—a peptide made of exactly three amino acids: L-lysine, L-glutamic acid, and L-aspartic acid. Its molecular weight is approximately 390 daltons. It belongs to the Khavinson bioregulator family, the same theoretical framework that produced Vilon and Thymogen, and it is one of nine compounds in Peptidings Cluster S.

What makes Vesugen unusual is that it may be the most recent member of the bioregulator family to enter the supplement market—introduced within the last decade—with the sparsest published evidence. While Vilon has mouse lifespan data and multiple in vitro studies, and Thymogen has a Russian pharmaceutical registration and one of the strongest animal studies in the entire Khavinson corpus, Vesugen exists on the basis of a single published in vitro study from the originating lab.

The vascular hypothesis is commercially appealing. Vascular health drives aging and cardiovascular disease, two conditions with enormous reader interest. A peptide that could restore endothelial function and lower atherosclerosis risk would be valuable. But commercial appeal is not the same as evidence, and Vesugen occupies an unusual editorial position in Cluster S: it is the thinnest evidence story among the "core three" bioregulators.

Additionally, Vesugen raises a specific structural question: it is the first three amino acids (KED) of four other Khavinson peptides—Pancragen (KEDW), Livagen (KEDA), Prostamax (KEDP), and Testagen (KEDG). If KED is truly the vascular peptide, why do longer peptides built on this same KED scaffold target the pancreas, liver, prostate, and testes? This specificity question cuts to the heart of the Khavinson mechanism hypothesis.

Quick Facts: Vesugen at a Glance

What Is Vesugen?

Pronunciation: VES-oo-jen

Vesugen is a synthetic tripeptide consisting of L-lysine, L-glutamic acid, and L-aspartic acid, joined in sequence by peptide bonds. Its molecular weight is approximately 390 Da. It is smaller than most therapeutic peptides—for comparison, BPC-157 contains 15 amino acids and weighs ~1419 Da—but larger than the dipeptides Vilon (275 Da) and Thymogen (333 Da).

Vesugen belongs to the Khavinson bioregulator family—ultrashort peptides (2–7 amino acids) developed by Vladimir Khavinson and colleagues. Like all members of this family, Vesugen is proposed to work not through conventional receptor agonism, but through direct nuclear entry and epigenetic gene modulation. The theory holds that small peptides can cross cell membranes and nuclear envelopes, interact directly with DNA, and modulate gene expression in an organ-specific manner.

The "organ-specific" claim is key to Vesugen's positioning. It is marketed as a vascular peptide—designed to target blood vessels and endothelial cell function. The specificity hypothesis is that the three-amino-acid sequence (Lys-Glu-Asp) encodes recognition information for vascular genes, while the same three-amino-acid core, extended with a different fourth amino acid, would encode different organ recognition: Pancragen (KEDW) for pancreas, Livagen (KEDA) for liver, Prostamax (KEDP) for prostate, and Testagen (KEDG) for testes.

This specificity architecture is at the center of Vesugen's evidence problem.

Origins and Discovery

Vesugen's history is less documented than Vilon or Thymogen. Unlike those compounds, which have multiple publications and clear development narratives in Russian medical literature, Vesugen appears to be a more recent synthesis—designed to extend the Khavinson bioregulator family into the vascular market.

The compound emerged in the latter phase of Vladimir Khavinson's research program, during a period when the bioregulator framework was being applied systematically to different organ systems. While Vilon (immune), Thymogen (immune, with pharmaceutical approval), and others had been developed and studied for decades, Vesugen and several other tetrapeptide variants appear to represent later-generation synthesis extensions of the core bioregulator theory.

The single published study on Vesugen—Khavinson & Tarnovskaya (2015)—is titled "Epigenetic aspects of peptidergic regulation of vascular endothelial cell function" and was distributed primarily as a PDF through khavinson.info rather than as a traditional journal publication indexed on PubMed. This is notable: all other core bioregulator compounds in Cluster S have at least one English-language peer-reviewed publication on PubMed. Vesugen's single reference exists outside that indexed literature.

Vladimir Khavinson died in January 2024. The future direction of bioregulator research, including whether new evidence on Vesugen will be published, remains uncertain.

Mechanism of Action

Vesugen's proposed mechanism follows the standard Khavinson bioregulation hypothesis with a vascular-specific application.

The Bioregulation Hypothesis Applied to Vascular Endothelium

According to the theory, Vesugen (Lys-Glu-Asp):

1. Enters endothelial cells — crosses the cell membrane due to its small molecular weight and cationic charge (lysine residue) 2. Crosses the nuclear membrane — reaching the nucleus where DNA-binding interactions can occur 3. Interacts with vascular gene promoters — specifically, promoter regions of genes involved in endothelial function, including those encoding endothelin-1 (vasoactive hormone), connexins (gap junction proteins), and sirtuins (stress response enzymes) 4. Decondenses age-related heterochromatin — reverses the chromatin condensation that accumulates in aging endothelial cells 5. Restores endothelial gene expression — reactivates genes needed for vascular tone regulation, gap junction formation, and cellular stress resistance

What the Single Published Study Shows

The 2015 Khavinson & Tarnovskaya study reported that Vesugen treatment of cultured endothelial cells produced three measurable changes:

1. Endothelin-1 normalization — ET-1 is a potent vasoconstrictor; elevated ET-1 is implicated in hypertension, atherosclerosis, and endothelial dysfunction. The study reported Vesugen reduced ET-1 expression toward normal levels. 2. Connexin restoration — Connexins are proteins that form gap junctions (communication channels between cells). Their loss in aging endothelium is associated with vascular dysfunction. Vesugen reportedly restored connexin expression. 3. Sirtuin-1 activation — SIRT1 is a NAD-dependent deacetylase linked to cellular stress resistance and longevity pathways. Vesugen reportedly increased SIRT1 activity in endothelial cells.

The Specificity Paradox

This is the central mechanistic challenge for Vesugen and all Khavinson bioregulators.

The three-amino-acid sequence Lys-Glu-Asp (K-E-D) is proposed to achieve vascular specificity—targeting vascular gene promoters rather than, say, pancreatic or hepatic gene promoters. Yet this same sequence appears at the N-terminus of four other Khavinson peptides, each with a different C-terminal amino acid:

• Pancragen (KEDW): K-E-D + W (tryptophan) → pancreatic specificity
• Livagen (KEDA): K-E-D + A (alanine) → hepatic specificity
• Prostamax (KEDP): K-E-D + P (proline) → prostatic specificity
• Testagen (KEDG): K-E-D + G (glycine) → testicular specificity

The hypothesis is that substituting the fourth amino acid redirects the peptide from vascular targets to pancreatic, hepatic, prostatic, or testicular targets. This would require:

1. The KED core to be recognized by a vascular-specific DNA-binding mechanism 2. The fourth amino acid to either switch that recognition off or redirect it to organ-specific gene promoters

Neither proposition has been demonstrated experimentally. Computational molecular modeling studies from Khavinson's group examined 400 possible dipeptide combinations and identified selectivity predictions—but these are theoretical, not experimentally validated in living systems.

No independent lab has tested or validated this specificity architecture.

Key Research Areas and Studies

In Vitro Endothelial Cell Study (2015)

Khavinson VKh, Tarnovskaya SI (2015): "Epigenetic aspects of peptidergic regulation of vascular endothelial cell function." Study examined the effect of Vesugen (KED) on cultured human endothelial cells. Endpoints included endothelin-1 expression (qPCR), connexin protein levels (Western blot), and sirtuin-1 activity (enzymatic assay). Results showed normalization of ET-1 expression, restoration of connexin levels, and increased SIRT1 activity relative to control endothelial cells. Published as a PDF on khavinson.info; not indexed on PubMed.

Study limitations: - Single cell culture study, not replicated - No dose-response characterization (no LD50, no ED50, no dose-response curve) - No mechanistic validation of proposed DNA-binding mechanism - No pharmacokinetic data (how peptide reaches endothelial cell nucleus) - No functional vascular outcomes (no vasodilation measurement, no atherosclerosis model, no endothelial dysfunction reversal) - Published outside indexed peer-reviewed literature

Proposed but Not Published Vascular Studies

References in vendor materials and promotional text suggest additional unpublished work on Vesugen in atherosclerosis models, vascular tone measurements, and endothelial dysfunction recovery—but these studies are not publicly available for audit. Their existence, designs, sample sizes, and results cannot be independently verified.

The Khavinson Evidence Problem

This section addresses the central evidence challenge that applies to Vesugen and every compound in the Khavinson bioregulator family. Vesugen's case is particularly acute.

Single Study Dependency

Vesugen's entire published evidence base consists of one in vitro study. All other core bioregulators in this cluster have at least two or three published studies. Vilon has five. Thymogen has four. By Khavinson bioregulator standards, Vesugen has exceptionally thin documentation.

That one study comes exclusively from Khavinson's lab. No Western laboratory has independently tested Vesugen's effects on endothelial cells, vascular tone, atherosclerosis, or any other outcome.

The Specificity Question is Sharpest Here

Vesugen makes a strong specificity claim—it targets vascular genes, not pancreatic or hepatic genes—yet it shares three of four amino acids (K, E, D) with four other peptides that supposedly target different organs. The mechanism by which a single amino acid substitution (W vs. A vs. P vs. G) redirects vascular peptide function to pancreatic, hepatic, prostatic, or testicular function has never been experimentally demonstrated.

This is not merely an unanswered question. It is the central architectural claim of the entire Khavinson peptide family, and it rests on computational predictions, not experimental validation in living systems.

Zero Animal Evidence

Vesugen has never been tested in a vascular disease model. No atherosclerosis studies. No hypertension studies. No endothelial dysfunction recovery studies. No lifespan studies. No comparison to known vascular interventions.

Compare this to Vilon (lifespan extension, tumor inhibition in mice) or Thymogen (lifespan extension, tumor inhibition in rats). Vesugen occupies a uniquely thin position: in vitro cell culture only.

Zero Human Evidence

No clinical trials. No pharmacokinetic studies. No dose-finding studies. No safety studies. No observational human data.

The Vascular Market Problem

Vascular health and cardiovascular aging drive enormous reader interest and supplement market sales. This commercial appeal may have influenced Vesugen's rapid introduction to the market despite minimal published evidence. A reader considering this peptide should understand that commercial positioning ("vascular health") is separate from evidence ("one in vitro study").

Claims vs. Evidence

The Human Evidence Landscape

There is no human evidence for Vesugen. The compound has never been administered to a human being in a published clinical trial, pharmacokinetic study, dose-finding study, safety study, or observational research protocol.

The only human data—and this is a stretch—would consist of unpublished vendor reports or anecdotal community use testimonials, which cannot be independently verified and do not constitute evidence.

What Would Need to Happen

For credible human evidence to emerge for Vesugen, a research group would need to:

1. Conduct a pharmacokinetic study in humans establishing that the tripeptide is absorbed (if injected or orally administered), reaches the vascular endothelium, and enters endothelial cell nuclei. This is foundational and does not exist for any Khavinson bioregulator. 2. Conduct a vascular function study measuring endothelial-dependent vasodilation, arterial stiffness, or atherosclerotic burden in subjects given Vesugen vs. placebo. No such study is published or registered. 3. Conduct a long-term safety study in a defined population establishing tolerable and non-toxic doses. None exists. 4. Establish a dose-response relationship showing that increasing doses produce increasing vascular benefit (or increased toxicity). No dose-response data exists for Vesugen.

None of these studies exist, are registered on ClinicalTrials.gov, or appear to be in development.

Safety, Risks, and Limitations

No Human Safety Data

No formal human safety, toxicology, or pharmacokinetic studies exist for Vesugen. The compound consists of three common amino acids (lysine, glutamic acid, aspartic acid), which might suggest a favorable safety profile—but common building blocks do not guarantee safety in a novel peptide form.

Theoretical Safety Argument

As a tripeptide of three standard amino acids, Vesugen is expected to be rapidly degraded by ubiquitous peptidases (exopeptidases, endopeptidases, carboxypeptidases) present throughout biological fluids. A short peptide of common amino acids is unlikely to accumulate, cause immune reactions, or produce off-target receptor effects. This theoretical safety argument is plausible but not validated by any formal toxicology studies.

Unknown Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) of Vesugen in humans is completely unknown. If injected subcutaneously, how much reaches intact form? How much is degraded in the interstitium? Does any reach the vascular endothelium? Does any enter endothelial cell nuclei? These are fundamental questions, and the answers are unknown.

The Unproven Mechanism Problem

The claim that Vesugen achieves vascular specificity rests on an unproven mechanism. If the specificity mechanism does not work as proposed—if the peptide instead acts non-specifically, or not at all—then the safety profile could differ from predictions. A peptide that enters random cells and nonspecifically modulates gene expression would be a different safety problem than a peptide that specifically targets vascular genes.

Legal and Regulatory Status

FDA Status

Vesugen has never been approved, reviewed, or submitted to the FDA. It is not an authorized pharmaceutical ingredient in the United States.

Russian Status

Vesugen is not a registered pharmaceutical in Russia. (Unlike Thymogen, which has a 1990 pharmaceutical registration, or the older tissue extracts like Thymalin, which are approved Russian drugs.)

WADA Status

Vesugen is not specifically listed on the WADA prohibited list. As a synthetic tripeptide, it may theoretically fall under S2 (Peptide hormones, growth factors, and related substances) depending on regulatory classification—but this is ambiguous for a three-amino-acid molecule with no established hormonal activity.

Market Availability

Vesugen is available through research peptide suppliers, typically as lyophilized powder labeled "for research purposes only." Purity, identity, and sterility are not regulated by any Western agency.

Research Protocols and Formulation Considerations

Chemical Composition

Vesugen is a synthetic tripeptide: L-Lysyl-L-Glutamyl-L-Aspartic acid. Molecular weight: ~390 Da. The cationic charge of the lysine residue is relevant to membrane permeability claims, though this has not been experimentally characterized for Vesugen.

Synthesis

Synthesized via standard solid-phase or solution-phase peptide synthesis. Tripeptides are trivial to synthesize by modern peptide chemistry standards.

Stability

As a tripeptide, Vesugen is susceptible to degradation by exopeptidases (which clip amino acids from the ends) and endopeptidases (which cleave internal peptide bonds). Stability in solution is expected to be limited. Lyophilized powder is the standard storage form.

Formulation

Research-grade Vesugen is typically supplied as lyophilized powder, reconstituted with bacteriostatic water or saline. The ability of Vesugen to remain intact through gastric acid and intestinal proteases (if taken orally) is unknown.

Dosing in Published Research

Route of Administration

Unknown. No published human or animal dosing studies exist. Vendor suggestions typically recommend subcutaneous injection in the microgram range, but these doses are extrapolated from other Khavinson compounds, not derived from any dose-finding study on Vesugen.

Doses in Published Studies

The single in vitro study (Khavinson & Tarnovskaya, 2015) does not specify the concentrations used in cell culture—a critical omission. Without dose-response data from even the single published study, it is impossible to extrapolate to in vivo doses.

Pharmacokinetics

Unknown in humans. Unknown in animals. The half-life of a free tripeptide in human plasma is expected to be very short (minutes) due to rapid enzymatic degradation by peptidases, but this has not been measured for Vesugen.

Dosing in Self-Experimentation Communities

WHY NEARLY EMPTY: Vesugen has minimal to nonexistent community adoption compared to mainstream peptides like BPC-157, TB-500, or MK-677. The Khavinson bioregulator market overall is niche, but Vesugen is newer and thinner-documented than even Vilon or Thymogen. No systematic community dosing data, dose-response reports, or protocol comparisons exist.

Vendor-Suggested Doses

Research peptide suppliers suggest doses in the range of 50–150 mcg/day subcutaneously, or sublingually. These doses are not derived from any published dose-finding study on Vesugen or any other tripeptide bioregulator. They appear to be extrapolated from Russian supplement protocols and represent vendor speculation rather than evidence-based dosing.

Frequency and Duration

Community protocols, insofar as they exist, typically suggest cycles of 10–20 days, with rest periods between cycles. This pattern mirrors Russian bioregulator supplement protocols but has no published pharmacological basis for Vesugen specifically.

Combination Stacks

Research into Vesugen combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Vesugen with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Vesugen is a synthetic tripeptide (Lys-Glu-Asp) marketed as a vascular bioregulator—designed to target blood vessel endothelium and restore vascular function through epigenetic gene modulation. It belongs to the Khavinson bioregulator family and is based on a 50-year research program proposing that ultrashort peptides can enter cell nuclei and regulate genes.

The evidence base is extraordinarily thin. A single in vitro study from 2015 shows that Vesugen treatment altered gene expression in cultured endothelial cells—specifically, modulating endothelin-1, connexin, and sirtuin-1 levels. This is the entire published evidence for the compound. No animal efficacy studies. No animal lifespan or carcinogenesis data. No human pharmacokinetic studies. No human dose-finding studies. No human clinical trials.

Vesugen's positioning as a vascular peptide is based on theory—the hypothesis that the three-amino-acid sequence (K-E-D) encodes recognition for vascular gene promoters. Yet this same K-E-D core appears at the N-terminus of four other compounds in the bioregulator family, each supposedly targeting different organs (pancreas, liver, prostate, testes). How a single amino acid substitution at the C-terminus redirects the peptide from vascular to pancreatic or hepatic targets has never been experimentally demonstrated.

Among the "core three" Khavinson bioregulators (Vilon, Thymogen, Vesugen), Vesugen is the thinnest evidence story. Thymogen is a registered Russian pharmaceutical with clinical use history and one of the strongest animal studies in the cluster. Vilon has multiple animal and in vitro studies and is the entry point to the bioregulator paradigm. Vesugen has one in vitro study and represents the hypothesis-stage end of the evidence spectrum.

Verdict Recapitulation

Vesugen earns "Thin Ice" rather than "Eyes Open" because it lacks the preclinical breadth and depth of other Tier 4 compounds in this cluster. Vilon has multiple animal studies (lifespan extension, tumor inhibition) and multiple in vitro studies, justifying "Eyes Open." Thymogen has pharmaceutical approval and the strongest animal study in Cluster S, justifying "Eyes Open." Vesugen has one in vitro study and zero animal efficacy data. The specificity question—how does the K-E-D core achieve vascular specificity when the same sequence appears in pancreatic, hepatic, prostatic, and testicular peptides?—remains completely unanswered. The Khavinson Evidence Problem applies to all nine compounds; Vesugen is where the problem is sharpest.

For readers considering Vesugen, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Vesugen

Further Reading and Resources

If you want to go deeper on Vesugen, the evidence landscape for khavinson bioregulators peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Khavinson Bioregulators Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Vesugen — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson VKh, Tarnovskaya SI. "Epigenetic aspects of peptidergic regulation of vascular endothelial cell function." 2015. [Available as PDF from khavinson.info; not indexed on PubMed]
2. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies." Advances in Gerontology. 2012;25(4):696–708. PMID 23734519
3. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results." Advances in Gerontology. 2013;26(1):20–37. PMID 24003726
4. Anisimov VN, Khavinson VKh, Morozov VG. "Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats." Biogerontology. 2000;1(1):55–59. PMID 11707921 [Reference for comparative context on Thymogen, a related bioregulator with stronger evidence]
5. Khavinson VKh et al. "Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line." International Journal of Molecular Sciences. 2022;23(8). PMC: 8999041 [Reference for comparative context on Vilon, a related bioregulator with stronger evidence]

---